<p>隨着美國市場面臨潛在波動，主要股指在政府關門截止日期前經歷輕微波動，投資者密切關注可能影響小盤股的經濟指標。在這樣的環境中，識別基本面強勁且具有增長潛力的鮮為人知的公司，對於那些希望在市場中發現隱藏機會的投資者來説至關重要。</p>
<h3>美國基本面強勁的十大未被發現的寶藏</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>負債權益比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Bancorp</td>
<td>75.89%</td>
<td>1.93%</td>
<td>-1.42%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Senstar Technologies</td>
<td>NA</td>
<td>-18.50%</td>
<td>29.50%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ASA Gold and Precious Metals</td>
<td>NA</td>
<td>12.79%</td>
<td>-0.59%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sound Financial Bancorp</td>
<td>34.70%</td>
<td>2.11%</td>
<td>-11.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Affinity Bancshares</td>
<td>43.51%</td>
<td>4.54%</td>
<td>8.05%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>SUI Group Holdings</td>
<td>NA</td>
<td>16.40%</td>
<td>-30.66%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Metalpha Technology Holding</td>
<td>NA</td>
<td>75.66%</td>
<td>28.60%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Valhi</td>
<td>44.30%</td>
<td>1.10%</td>
<td>-1.40%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Rich Sparkle Holdings</td>
<td>26.73%</td>
<td>-6.13%</td>
<td>1.75%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Solesence</td>
<td>91.26%</td>
<td>23.30%</td>
<td>4.70%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國基本面強勁的未被發現的寶藏篩選器中的 286 只股票的完整列表。</p>
<p>以下是篩選器中一些選擇的預覽。</p>
<h2>Gyre Therapeutics (GYRE)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Gyre Therapeutics, Inc.是一家制藥公司，專注於開發和商業化小分子藥物，用於針對器官纖維化的抗炎和抗纖維化治療，市值為 6.5032 億美元。</p>
<p><strong>運營：</strong> Gyre Therapeutics 主要通過其 Gyre Pharmaceuticals 部門產生收入，該部門報告收入為 1.0219 億美元。</p>
<p>Gyre Therapeutics 是一家靈活的生物技術公司，最近實現了盈利，但預計未來三年年收益將下降 84.3%。儘管如此，收入預計每年增長近 17%。該公司無債務，且過去的盈利質量高。最近的事件包括其被納入 S&amp;P 全球 BMI 指數，以及 Ping Zhang 擔任臨時首席執行官的領導變更。對於 2025 年，Gyre 預計收入在 1.18 億至 1.28 億美元之間，受新產品推出如 Etorel 和 Contiva 以及 ETUARY®銷售的推動。</p>
<ul>
<li>解鎖我們對 Gyre Therapeutics 股票分析的全面見解，詳見本健康報告。</li>
<li>探索歷史數據，以跟蹤 Gyre Therapeutics 隨時間的表現，詳見我們的過去部分。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97ccc20e-42f8-49ae-93d0-40fda938d4d8/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97ccc20e-42f8-49ae-93d0-40fda938d4d8/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 9 月的 GYRE 收益和收入增長</p>
<h2>HarborOne Bancorp (HONE)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> HarborOne Bancorp, Inc.為個人、家庭、中小型企業和市政當局提供金融服務，市值為 5.5817 億美元。</p>
<p><strong>運營：</strong> HarborOne Bancorp 主要通過 HarborOne Bank 產生收入，貢獻 1.4555 億美元，以及 HarborOne Mortgage 貢獻 1935 萬美元。該公司展現出值得注意的淨利潤率趨勢，對整體盈利能力有重要影響。</p>
<p>HarborOne Bancorp 總資產為 56 億美元，股本為 5.801 億美元，展現出強大的財務基礎。總存款為 45 億美元，貸款為 47 億美元，強調了強勁的貸款活動，主要由低風險資金來源支持——89% 來自客户存款。該銀行的壞賬準備金充足，達到 147%，不良貸款管理良好，比例為 0.7%。過去一年，收益增長了 65.9%，顯著超過行業增長率 12.8%。最近，HarborOne 宣佈每股季度股息為 0.09 美元，反映出其在穩定的收益表現和高質量的盈利歷史中對股東回報的承諾。</p>
<ul>
<li>在我們的健康報告中更深入地瞭解 HarborOne Bancorp 的潛力。</li>
<li>通過查看我們的歷史表現報告，獲取 HarborOne Bancorp 的歷史表現見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9eabf449-2ac8-482e-9d39-8d51fa144fa5/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9eabf449-2ac8-482e-9d39-8d51fa144fa5/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 9 月的 HONE 收益和收入增長</p>
<h2>Spok Holdings (SPOK)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Spok Holdings, Inc.通過其子公司 Spok, Inc.在全球提供醫療通信解決方案，市值為 3.5890 億美元。</p>
<p><strong>運營：</strong> Spok Holdings 主要通過其臨牀通信與協作業務產生收入，金額為 1.4074 億美元。</p>
<p>Spok Holdings 是一家靈活的醫療通信行業參與者，正在向 SaaS 模型過渡，這提升了其經常性收入和利潤率。五年來無債務，且交易價格低於其公允價值估計的 56.3%，Spok 似乎被低估。該公司報告 2025 年第二季度的收益，銷售額為 1725 萬美元，淨收入為 455 萬美元，顯示出較去年增長。儘管有這些積極因素，但無線服務收入下降等挑戰依然存在，預計年增長率為 1.1%。該股票的目標價格表明從當前水平（約每股 17.53 美元）有潛在上漲空間。</p>
<ul>
<li>Spok Holdings 向 SaaS 模型的過渡提升了經常性收入和利潤率。點擊這裏探索 Spok Holdings 戰略轉型的完整敍述。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ffb7b4ca-5fc4-4ff3-9e0d-03de98dd33f7/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ffb7b4ca-5fc4-4ff3-9e0d-03de98dd33f7/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 9 月的 SPOK 收益和收入增長</p>
<h2>接下來該如何做？</h2>
<ul>
<li>在這裏調查我們 286 只具有強大基本面的美國未被發現的優質股票。</li>
<li>是這些公司的股東之一嗎？確保您不會被突發情況所困擾，通過在 Simply Wall St 中添加您的投資組合，以便及時獲取重大股票動態的提醒。</li>
<li>Simply Wall St 是一款為長期股票投資者設計的革命性應用程序，免費且覆蓋全球所有市場。</li>
</ul>
<h2>對其他可能性感興趣？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

GYRE

Spok控股

<p>美國市場正經歷波動，促使投資者尋求基本面強勁的鮮為人知的公司。值得關注的潛在投資機會包括 Gyre Therapeutics、HarborOne Bancorp 和 Spok Holdings，這些公司在市場挑戰中展現出增長潛力。Gyre 專注於抗炎藥物，HarborOne 提供具有強大利潤率的金融服務，而 Spok 則正在向醫療通信的 SaaS 模式轉型。這些公司因其穩健的財務狀況和增長前景而受到關注，成為尋求市場隱藏機會的投資者的吸引選項</p>

<p>As the U.S. market faces potential volatility with major stock indexes experiencing slight fluctuations ahead of a government shutdown deadline, investors are keenly observing economic indicators that could impact small-cap stocks. In such an environment, identifying lesser-known companies with strong fundamentals and growth potential can be crucial for those looking to uncover hidden opportunities in the market.</p>
<div class="lb-trans"><p>隨着美國市場面臨潛在波動，主要股指在政府關門截止日期前經歷輕微波動，投資者密切關注可能影響小盤股的經濟指標。在這樣的環境中，識別基本面強勁且具有增長潛力的鮮為人知的公司，對於那些希望在市場中發現隱藏機會的投資者來説至關重要。</p>
</div><h3>Top 10 Undiscovered Gems With Strong Fundamentals In The United States</h3>
<div class="lb-trans"><h3>美國基本面強勁的十大未被發現的寶藏</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Debt To Equity</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Health Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Bancorp</td>
<td>75.89%</td>
<td>1.93%</td>
<td>-1.42%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Senstar Technologies</td>
<td>NA</td>
<td>-18.50%</td>
<td>29.50%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ASA Gold and Precious Metals</td>
<td>NA</td>
<td>12.79%</td>
<td>-0.59%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sound Financial Bancorp</td>
<td>34.70%</td>
<td>2.11%</td>
<td>-11.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Affinity Bancshares</td>
<td>43.51%</td>
<td>4.54%</td>
<td>8.05%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>SUI Group Holdings</td>
<td>NA</td>
<td>16.40%</td>
<td>-30.66%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Metalpha Technology Holding</td>
<td>NA</td>
<td>75.66%</td>
<td>28.60%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Valhi</td>
<td>44.30%</td>
<td>1.10%</td>
<td>-1.40%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Rich Sparkle Holdings</td>
<td>26.73%</td>
<td>-6.13%</td>
<td>1.75%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Solesence</td>
<td>91.26%</td>
<td>23.30%</td>
<td>4.70%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>負債權益比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Bancorp</td>
<td>75.89%</td>
<td>1.93%</td>
<td>-1.42%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Senstar Technologies</td>
<td>NA</td>
<td>-18.50%</td>
<td>29.50%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ASA Gold and Precious Metals</td>
<td>NA</td>
<td>12.79%</td>
<td>-0.59%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sound Financial Bancorp</td>
<td>34.70%</td>
<td>2.11%</td>
<td>-11.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Affinity Bancshares</td>
<td>43.51%</td>
<td>4.54%</td>
<td>8.05%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>SUI Group Holdings</td>
<td>NA</td>
<td>16.40%</td>
<td>-30.66%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Metalpha Technology Holding</td>
<td>NA</td>
<td>75.66%</td>
<td>28.60%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Valhi</td>
<td>44.30%</td>
<td>1.10%</td>
<td>-1.40%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Rich Sparkle Holdings</td>
<td>26.73%</td>
<td>-6.13%</td>
<td>1.75%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Solesence</td>
<td>91.26%</td>
<td>23.30%</td>
<td>4.70%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 286 stocks from our US Undiscovered Gems With Strong Fundamentals screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國基本面強勁的未被發現的寶藏篩選器中的 286 只股票的完整列表。</p>
</div><p>Here's a peek at a few of the choices from the screener.</p>
<div class="lb-trans"><p>以下是篩選器中一些選擇的預覽。</p>
</div><h2>Gyre Therapeutics (GYRE)</h2>
<div class="lb-trans"><h2>Gyre Therapeutics (GYRE)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing small-molecule drugs for anti-inflammatory and anti-fibrotic treatments targeting organ fibrosis, with a market cap of $650.32 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Gyre Therapeutics, Inc.是一家制藥公司，專注於開發和商業化小分子藥物，用於針對器官纖維化的抗炎和抗纖維化治療，市值為 6.5032 億美元。</p>
</div><p><strong>Operations:</strong> Gyre Therapeutics generates revenue primarily through its Gyre Pharmaceuticals segment, which reported $102.19 million in revenue.</p>
<div class="lb-trans"><p><strong>運營：</strong> Gyre Therapeutics 主要通過其 Gyre Pharmaceuticals 部門產生收入，該部門報告收入為 1.0219 億美元。</p>
</div><p>Gyre Therapeutics, a nimble player in the biotech scene, has recently become profitable, yet faces a forecasted earnings dip of 84.3% annually over the next three years. Despite this, revenue is expected to grow by nearly 17% per year. The company remains debt-free and boasts high-quality past earnings. Recent events include its addition to the S&amp;P Global BMI Index and leadership changes with Ping Zhang stepping in as interim CEO. For 2025, Gyre anticipates revenues between US$118 million and US$128 million, fueled by new product launches like Etorel and Contiva alongside ETUARY® sales.</p>
<div class="lb-trans"><p>Gyre Therapeutics 是一家靈活的生物技術公司，最近實現了盈利，但預計未來三年年收益將下降 84.3%。儘管如此，收入預計每年增長近 17%。該公司無債務，且過去的盈利質量高。最近的事件包括其被納入 S&amp;P 全球 BMI 指數，以及 Ping Zhang 擔任臨時首席執行官的領導變更。對於 2025 年，Gyre 預計收入在 1.18 億至 1.28 億美元之間，受新產品推出如 Etorel 和 Contiva 以及 ETUARY®銷售的推動。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Gyre Therapeutics stock in this health report.</li>
<li>Explore historical data to track Gyre Therapeutics' performance over time in our Past section.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖我們對 Gyre Therapeutics 股票分析的全面見解，詳見本健康報告。</li>
<li>探索歷史數據，以跟蹤 Gyre Therapeutics 隨時間的表現，詳見我們的過去部分。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97ccc20e-42f8-49ae-93d0-40fda938d4d8/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/97ccc20e-42f8-49ae-93d0-40fda938d4d8/chart/earnings-and-revenue-growth"/></p>
<p>GYRE Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 GYRE 收益和收入增長</p>
</div><h2>HarborOne Bancorp (HONE)</h2>
<div class="lb-trans"><h2>HarborOne Bancorp (HONE)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> HarborOne Bancorp, Inc. offers financial services to individuals, families, small and mid-size businesses, and municipalities with a market capitalization of $558.17 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> HarborOne Bancorp, Inc.為個人、家庭、中小型企業和市政當局提供金融服務，市值為 5.5817 億美元。</p>
</div><p><strong>Operations:</strong> HarborOne Bancorp generates revenue primarily through HarborOne Bank, contributing $145.55 million, and HarborOne Mortgage with $19.35 million. The company exhibits a net profit margin trend worth noting for its implications on overall profitability.</p>
<div class="lb-trans"><p><strong>運營：</strong> HarborOne Bancorp 主要通過 HarborOne Bank 產生收入，貢獻 1.4555 億美元，以及 HarborOne Mortgage 貢獻 1935 萬美元。該公司展現出值得注意的淨利潤率趨勢，對整體盈利能力有重要影響。</p>
</div><p>HarborOne Bancorp, with total assets of US$5.6 billion and equity of US$580.1 million, showcases a robust financial foundation. Total deposits stand at US$4.5 billion against loans of US$4.7 billion, underlining strong lending activity supported by primarily low-risk funding sources—89% from customer deposits. The bank's allowance for bad loans is sufficient at 147%, with non-performing loans well-managed at 0.7%. Earnings have surged by 65.9% over the past year, notably outpacing the industry growth rate of 12.8%. Recently, HarborOne declared a quarterly dividend of $0.09 per share, reflecting its commitment to shareholder returns amidst steady earnings performance and high-quality earnings history.</p>
<div class="lb-trans"><p>HarborOne Bancorp 總資產為 56 億美元，股本為 5.801 億美元，展現出強大的財務基礎。總存款為 45 億美元，貸款為 47 億美元，強調了強勁的貸款活動，主要由低風險資金來源支持——89% 來自客户存款。該銀行的壞賬準備金充足，達到 147%，不良貸款管理良好，比例為 0.7%。過去一年，收益增長了 65.9%，顯著超過行業增長率 12.8%。最近，HarborOne 宣佈每股季度股息為 0.09 美元，反映出其在穩定的收益表現和高質量的盈利歷史中對股東回報的承諾。</p>
</div><ul>
<li>Take a closer look at HarborOne Bancorp's potential here in our health report.</li>
<li>Gain insights into HarborOne Bancorp's historical performance by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的健康報告中更深入地瞭解 HarborOne Bancorp 的潛力。</li>
<li>通過查看我們的歷史表現報告，獲取 HarborOne Bancorp 的歷史表現見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9eabf449-2ac8-482e-9d39-8d51fa144fa5/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/9eabf449-2ac8-482e-9d39-8d51fa144fa5/chart/earnings-and-revenue-growth"/></p>
<p>HONE Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 HONE 收益和收入增長</p>
</div><h2>Spok Holdings (SPOK)</h2>
<div class="lb-trans"><h2>Spok Holdings (SPOK)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Spok Holdings, Inc. offers healthcare communication solutions globally through its subsidiary, Spok, Inc., and has a market capitalization of $358.90 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Spok Holdings, Inc.通過其子公司 Spok, Inc.在全球提供醫療通信解決方案，市值為 3.5890 億美元。</p>
</div><p><strong>Operations:</strong> Spok Holdings generates revenue primarily from its Clinical Communication and Collaboration business, amounting to $140.74 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> Spok Holdings 主要通過其臨牀通信與協作業務產生收入，金額為 1.4074 億美元。</p>
</div><p>Spok Holdings, a nimble player in the healthcare communication sector, is navigating a transition to a SaaS model, which is boosting its recurring revenue and margins. With no debt for five years and trading at 56.3% below its fair value estimate, Spok seems undervalued. The company reported Q2 2025 earnings with sales of US$17.25 million and net income of US$4.55 million, showing growth from the previous year. Despite these positives, challenges like declining wireless service revenue persist alongside modest projected annual growth of 1.1%. The stock's target price suggests potential upside from current levels around US$17.53 per share.</p>
<div class="lb-trans"><p>Spok Holdings 是一家靈活的醫療通信行業參與者，正在向 SaaS 模型過渡，這提升了其經常性收入和利潤率。五年來無債務，且交易價格低於其公允價值估計的 56.3%，Spok 似乎被低估。該公司報告 2025 年第二季度的收益，銷售額為 1725 萬美元，淨收入為 455 萬美元，顯示出較去年增長。儘管有這些積極因素，但無線服務收入下降等挑戰依然存在，預計年增長率為 1.1%。該股票的目標價格表明從當前水平（約每股 17.53 美元）有潛在上漲空間。</p>
</div><ul>
<li>Spok Holdings' transition to a SaaS model boosts recurring revenue and margins. Click here to explore the full narrative on Spok Holdings' strategic shift.</li>
</ul>
<div class="lb-trans"><ul>
<li>Spok Holdings 向 SaaS 模型的過渡提升了經常性收入和利潤率。點擊這裏探索 Spok Holdings 戰略轉型的完整敍述。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ffb7b4ca-5fc4-4ff3-9e0d-03de98dd33f7/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/ffb7b4ca-5fc4-4ff3-9e0d-03de98dd33f7/chart/earnings-and-revenue-growth"/></p>
<p>SPOK Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SPOK 收益和收入增長</p>
</div><h2>Where To Now?</h2>
<div class="lb-trans"><h2>接下來該如何做？</h2>
</div><ul>
<li>Investigate our full lineup of 286 US Undiscovered Gems With Strong Fundamentals right here.</li>
<li>Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.</li>
<li>Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏調查我們 286 只具有強大基本面的美國未被發現的優質股票。</li>
<li>是這些公司的股東之一嗎？確保您不會被突發情況所困擾，通過在 Simply Wall St 中添加您的投資組合，以便及時獲取重大股票動態的提醒。</li>
<li>Simply Wall St 是一款為長期股票投資者設計的革命性應用程序，免費且覆蓋全球所有市場。</li>
</ul>
</div><h2>Interested In Other Possibilities?</h2>
<div class="lb-trans"><h2>對其他可能性感興趣？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

發掘美國市場中的 3 個尚未被發現的瑰寶